Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14570
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Prachayasittikul S. | |
dc.contributor.author | Worachartcheewan A. | |
dc.contributor.author | Nantasenamat C. | |
dc.contributor.author | Chinworrungsee M. | |
dc.contributor.author | Sornsongkhram N. | |
dc.contributor.author | Ruchirawat S. | |
dc.contributor.author | Prachayasittikul V. | |
dc.date.accessioned | 2021-04-05T03:35:38Z | - |
dc.date.available | 2021-04-05T03:35:38Z | - |
dc.date.issued | 2011 | |
dc.identifier.issn | 2235234 | |
dc.identifier.other | 2-s2.0-79151482944 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/14570 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-79151482944&doi=10.1016%2fj.ejmech.2010.12.009&partnerID=40&md5=2174a7714d042ee5e89f1cfb500ed788 | |
dc.description.abstract | Considering that some thiopyrimidines were previously reported as potential therapeutics, the present study achieved novel analogs of bioactive 2-substituted thiopyrimidines-4-(3H)-ones via base catalyzed alkylation reaction of 2-thiouracil using alkyl and aralkyl bromides. The title compounds were 2-(1-butylthio)pyrimidine-4(3H)-one (5a), 2-(2-butylthio)pyrimidine-4(3H)-one (5b), 2-(cyclohexylmethylthio)pyrimidine-4(3H)-one (5c), 2-(benzylthio) pyrimidine-4(3H)-one (5d) and 2-(1-adamantylthio)pyrimidine-4(3H)-one (5e). Bioactivity tests revealed that thiopyrimidines 5a, 5c, 5d and 5e exhibited antimicrobial activity. The thiopyrimidine-4-one (5c) showed complete inhibition against Streptococcus pyogenes and Branhamella catarrhalis as well as antifungal action against Candida albicans. Significantly, the 1-adamantylthiopyrimidine (5e) was shown to be the most potent cytotoxic compound against multidrug-resistant small cell lung cancer (H69AR). Their structure-activity relationships were discussed. © 2010 Elsevier Masson SAS. All rights reserved. | |
dc.subject | 2 (1 adamantylthio)pyrimidin 4(3h) one | |
dc.subject | 2 (1 butylthio)pyrimidin 4(3h) one | |
dc.subject | 2 (2 butylthio)pyrimidin 4(3h) one | |
dc.subject | 2 (benzylthio)pyrimidin 4(3h) one | |
dc.subject | 2 (cyclohexylmethylthio)pyrimidin 4(3h) one | |
dc.subject | 2 thiopyrimidine 4 one | |
dc.subject | ampicillin | |
dc.subject | antiinfective agent | |
dc.subject | antineoplastic agent | |
dc.subject | bromine derivative | |
dc.subject | etoposide | |
dc.subject | pyrimidine derivative | |
dc.subject | thiouracil | |
dc.subject | unclassified drug | |
dc.subject | Aeromonas hydrophila | |
dc.subject | alkylation | |
dc.subject | antibacterial activity | |
dc.subject | antifungal activity | |
dc.subject | antimalarial activity | |
dc.subject | antimicrobial activity | |
dc.subject | antineoplastic activity | |
dc.subject | article | |
dc.subject | Bacillus cereus | |
dc.subject | Bacillus subtilis | |
dc.subject | cancer resistance | |
dc.subject | Candida albicans | |
dc.subject | Citrobacter freundii | |
dc.subject | controlled study | |
dc.subject | Corynebacterium diphtheriae | |
dc.subject | cytotoxicity | |
dc.subject | drug activity | |
dc.subject | drug synthesis | |
dc.subject | Edwardsiella tarda | |
dc.subject | Enterococcus faecalis | |
dc.subject | Escherichia coli | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | Klebsiella pneumoniae | |
dc.subject | Listeria monocytogenes | |
dc.subject | lung small cell cancer | |
dc.subject | Micrococcus luteus | |
dc.subject | Moraxella catarrhalis | |
dc.subject | Morganella morganii | |
dc.subject | Neisseria mucosa | |
dc.subject | nonhuman | |
dc.subject | Plasmodium falciparum | |
dc.subject | Plesiomonas shigelloides | |
dc.subject | Pseudomonas aeruginosa | |
dc.subject | Salmonella choleraesuis | |
dc.subject | Salmonella typhimurium | |
dc.subject | Shigella dysenteriae | |
dc.subject | Staphylococcus aureus | |
dc.subject | Staphylococcus epidermidis | |
dc.subject | Stenotrophomonas maltophilia | |
dc.subject | Streptococcus pyogenes | |
dc.subject | structure activity relation | |
dc.subject | Vibrio cholerae | |
dc.subject | Vibrio mimicus | |
dc.subject | yeast | |
dc.subject | Animals | |
dc.subject | Anti-Bacterial Agents | |
dc.subject | Antifungal Agents | |
dc.subject | Antimalarials | |
dc.subject | Antineoplastic Agents | |
dc.subject | Candida albicans | |
dc.subject | Cell Line, Tumor | |
dc.subject | Cell Proliferation | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Drug Screening Assays, Antitumor | |
dc.subject | Humans | |
dc.subject | Mice | |
dc.subject | Microbial Sensitivity Tests | |
dc.subject | Molecular Structure | |
dc.subject | Moraxella (Branhamella) catarrhalis | |
dc.subject | Parasitic Sensitivity Tests | |
dc.subject | Plasmodium falciparum | |
dc.subject | Pyrimidinones | |
dc.subject | Stereoisomerism | |
dc.subject | Streptococcus pyogenes | |
dc.subject | Structure-Activity Relationship | |
dc.title | Synthesis and structure-activity relationship of 2-thiopyrimidine-4-one analogs as antimicrobial and anticancer agents | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | European Journal of Medicinal Chemistry. Vol 46, No.2 (2011), p.738-742 | |
dc.identifier.doi | 10.1016/j.ejmech.2010.12.009 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.